Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 294-268-8 | CAS number: 91697-07-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
No acute oral toxicity study is available for the target substance C16 -18 Sulfosuccinate.
The acute oral toxicity of the source substance C12-18 Sulfosuccinate is low. A key study is available with test item containing ≥ 90 % a.i. dosed by gavage in Wistar rats at 480, 1400 and 2000 mg/kg bw (BASF SE, 1987). Five (for low and mid dose) and two rats (for high dose) were used per sex. Clinical observations and gross macroscopic observations were observed at all dose levels. The LD50 was between 580 and 1400 mg/kg for male and female rats, and therefore the test item was considered harmful. Two supporting studies for acute oral toxicity by gavage were available. In the first supporting study, the test item containing ≥ 90 % a.i. was tested by oral gavage in male and female Wistar rats (BASF SE, 1986). The male LD50was > 2000mg/kg bw, the female male LD50was ca. 1400 mg/kg bw. In the second supporting study, the test item containing ≥ 90 % a.i. was tested by oral gavage in male Wistar rats (BASF SE, 1969). The test item was administered by single gavage in aqua dest. as solvent and an application volume of 20 mL/kg bw to fasted animals at doses of 1580, 1990, 2510 and 3160 mg/kg bw. Ten male rats were used per sex and dose. The LD50 was 2400 mg/kg bw.
In conclusion, the test item is considered of low toxic potential based on the most dentrimental study, indicating an LD50 between 580 and 1400 mg/kg bw. For the LD50 value, 580 mg/kg bw was used as worst case value.
Acute dermal toxicity:
No acute dermal toxicity study is availabe for the target substance C16 -18 Sulfosuccinate.
The acute dermal toxicity of the source substance C12-18 Sulfosuccinate is low. A key study for acute dermal toxicity according to OECD 402 was conducted with the substance containing > 95 % a.i. (BASF, 2013). A dose level of 2000 mg/kg bw was employed. The test item was applied once for 24 hours on the shaved intact dorsal skin of rats (5 cm x 6 cm, approx. 1/10 of body surface). This treatment was followed by an observation period of 2 weeks. There were no signs of toxicity and no deaths. A very slight erythema (barely perceptible) on the application site was observed in all 5 of 5 male and 5 of 5 female animals on test days 2 and 3. All animals gained the expected body weight throughout the whole experimental period. No macroscopic findings were observed at necropsy. In conclusion, as LD50exceeds 2000 mg/kg bw and only very slight erythema was observed, there is no acute dermal toxicity hazard.
The same is assumed for C16 -18 Sulfosuccinate.
Inhalation toxicity testing was waived based upon the fact that acute inhalation exposure as such is very unlikely for sulfosuccinates due to their substance properties.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 580 mg/kg bw
- Quality of whole database:
- High quality (Klimish 2)
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- High quality (Klimisch 1)
Additional information
Acute oral toxicity
No acute oral toxicity study is available for the target substance C16 -18 Sulfosuccinate. The acute oral toxicity of a close homolog C12 -18 Sulfosuccinate (containing >= 90% act. ingr.) was tested by gavage in Wistar rats at dose levels of 580, 1400 and 2000 mg/kg bw. The test compound was administered by single gavage in aqua dest. as solvent and application volume of 20ml/kg bw to fasted animals. Two (low and mid dose) or five (high dose) were used per sex and dose. Clinical observations and gross macroscopic observations were observed at all dose levels. The LD50 was < 1400 mg/kg bw and > 580 mg/kg bw for female and male rats.
Based on the information of the close homolog, C16 -18 Sulfosuccinate was considered harmful if swallowed.
No acute dermal toxicity study is availabe for the target substance C16 -18 Sulfosuccinate. Acute dermal toxicity testing in rats of a close homolog, C12 -18 Sulfosuccinate was conducted. One dose level of 2000 mg/kg bw was employed. The test item was applied once for 24 hours on the shaved intact dorsal skin of rats (5cm x 6cm, approx. 1/10 of body surface). This treatment was followed by an observation period of 2 weeks. There were no signs of toxicity and no deaths. A very slight erythema (barely perceptible) on the application site was observed in all animals on test days 2 and 3. All nimals gained the expected body weight throughout the whole experimental period. No macroscopic findings were observed at necropsy. In conclusion, as the LD50 exceeds 2000 mg/kg bw and only very slight erythema was observed, there is no acute dermal toxicity hazard.
Based on the information of the homolog, C16 -18 Sulfosuccinate is also not expected to be acute toxic after dermal application.
Inhalation toxicity testing was waived based upon the fact that acute inhalation exposure as such is very unlikely for sulfosuccinates due to their substance properties.
Acute inhalation toxicity
Inhalation is very unlikely due to large particle size, low vapour pressure and high hydrophilic properties of the substance. Based on these and other physicochemical properties, the inhalation route is not appropriate; the oral and dermal route of administration are therefore applied as first and second relevant routes (ECHA R7a Guidance p 342). Additional inhalation testing would therefore neither lead to a better risk assessment, nor improve the safety of applications. Based on the argumentation summarized above an acute inhalation toxicity study is waived.
Justification for classification or non-classification
The test substance is classified as HARMFUL and the symbol 'Xn' and risk phrase R 22 'HARMFUL IF SWALLOWED' are required according the EU labelling regulations Commision directive 93/21/EEC. According to CLP regulation (No. 1272/2008 of 16 December 2008), Category 4 classification is proposed for acute oral toxicity with signal word 'WARNING'.
Based on these results and according to the EC Directive (No.93/21/EEC) and CLP (No. 1272/2008 of 16 December 2008), the test substance does not have to be classified and has no obligatory labelling requirement for dermal toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.